Design, synthesis, and biological evaluation of aminoboronic acids as growth-factor receptor inhibitors of EGFR and VEGFR-1 tyrosine kinases

被引:38
作者
Asano, T
Nakamura, H [1 ]
Uehara, Y
Yamamoto, Y
机构
[1] Gakushuin Univ, Fac Sci, Dept Chem, Tokyo 1718588, Japan
[2] Tohoku Univ, Grad Sch Sci, Dept Chem, Sendai, Miyagi 9808578, Japan
[3] Natl Inst Infect Dis, Dept Bioact Mol, Tokyo 1628640, Japan
关键词
bioorganic chemistry; boron; growth-factor receptors; tyrosine kinase inhibitor;
D O I
10.1002/cbic.200300748
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of aminoboronic acids was synthesized abased on the structure of lavendustin pharmocophore 1. Their inhibitory activities against the epidermal growth-factor receptor (EGFR) and vascular endothelial growth-factor receptor-1 (VEGFR-1, Flt-1) protein tyrosine kinases, and various protein kinases, PKA, PKC, PTK, and eEF2K were evaluated. Selective inhibition activities were observed in a series of aminoboronic acids. 4-Methoxy-3-((2-methoxyphenylamino)methyl)phenylboronic acid 10 inhibited EGFR tyrosine kinase, whereas 4-(2,5-dihydroxybenzylamino)phenyl boronic acid 72 inhibited Flt-1 protein kinase, although lavendustin pharmacophore 1 inhibited both EGFR and Flt-1 kinases at a compound concentration of 1.0 mug mL(-1). The selective inhibition of EGFR by 70 is considered to be due to the substitution of the dihydroxy groups on the benzyl moiety for a boronic acid group at the para position, whereas the selective inhibition of Flt-1 by 12 is due to the substitution of the carboxyl group on the aniline moiety in the lavendustin pharmacophore 1 for a boronic acid group.
引用
收藏
页码:483 / 490
页数:8
相关论文
共 37 条
[11]   Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors [J].
Hamby, JM ;
Showalter, HDH .
PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) :169-193
[12]  
Hawthorne M. F, 1993, ANGEW CHEM, V105, P997
[13]   THE ROLE OF CHEMISTRY IN THE DEVELOPMENT OF BORON NEUTRON-CAPTURE THERAPY OF CANCER [J].
HAWTHORNE, MF .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1993, 32 (07) :950-984
[14]  
KATS BA, 1995, BIOCHEMISTRY-US, V34, P8264
[15]  
KOEHLER KA, 1971, BIOCHEMISTRY-US, V10, P2477
[16]   Protease inhibitors: Current status and future prospects [J].
Leung, D ;
Abbenante, G ;
Fairlie, DP .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (03) :305-341
[17]   TYROSINE KINASE INHIBITION - AN APPROACH TO DRUG DEVELOPMENT [J].
LEVITZKI, A ;
GAZIT, A .
SCIENCE, 1995, 267 (5205) :1782-1788
[18]   Protein tyrosine kinase inhibitors as novel therapeutic agents [J].
Levitzki, A .
PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) :231-239
[19]   ALPHA-HALO BORONIC ESTERS - INTERMEDIATES FOR STEREODIRECTED SYNTHESIS [J].
MATTESON, DS .
CHEMICAL REVIEWS, 1989, 89 (07) :1535-1551
[20]   Asymmetric alkyldifluoroboranes and their use in secondary amine synthesis [J].
Matteson, DS ;
Kim, GY .
ORGANIC LETTERS, 2002, 4 (13) :2153-2155